These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37532078)

  • 21. Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.
    Malinowska IA; Lee N; Kumar V; Thiele EA; Franz DN; Ashwal S; Sagalowsky A; Dimario FJ; Cutler D; Krueger D; Camposano S; Paolini J; Dabora SL
    PLoS One; 2013; 8(2):e56199. PubMed ID: 23437092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
    Moavero R; Coniglio A; Garaci F; Curatolo P
    Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.
    Bissler JJ; Budde K; Sauter M; Franz DN; Zonnenberg BA; Frost MD; Belousova E; Berkowitz N; Ridolfi A; Christopher Kingswood J
    Nephrol Dial Transplant; 2019 Jun; 34(6):1000-1008. PubMed ID: 30053159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Living Donor Preemptive Kidney Transplantation in Tuberous Sclerosis Complex Patient and the Role of Mammalian Target of Rapamycin Inhibitor: A Case Report.
    Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E
    Transplant Proc; 2020 Oct; 52(8):2520-2523. PubMed ID: 32448667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association.
    Aydin H; Magi-Galluzzi C; Lane BR; Sercia L; Lopez JI; Rini BI; Zhou M
    Am J Surg Pathol; 2009 Feb; 33(2):289-97. PubMed ID: 18852677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
    Samuels JA
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel mechanism of regulation of fibrosis in kidney tumor with tuberous sclerosis.
    Liang S; Cuevas G; Tizani S; Salas T; Liu H; Li B; Habib SL
    Mol Cancer; 2013 May; 12():49. PubMed ID: 23705901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
    Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
    Yeşil Ş; Kurucu B; Hamamcı MB; Yılmaz Ş; Şahin G
    Childs Nerv Syst; 2024 Mar; 40(3):831-837. PubMed ID: 37947859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas.
    Swallow E; King S; Song J; Peeples M; Signorovitch JE; Liu Z; Prestifilippo J; Frost M; Kohrman M; Korf B; Krueger D; Sparagana S
    Urology; 2017 Jun; 104():110-114. PubMed ID: 28263820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
    Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
    J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
    Sadowski K; Kotulska K; Jóźwiak S
    Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tuberous sclerosis complex: Hamartin and tuberin expression in renal cysts and its discordant expression in renal neoplasms.
    Bonsib SM; Boils C; Gokden N; Grignon D; Gu X; Higgins JP; Leroy X; McKenney JK; Nasr SH; Phillips C; Sangoi AR; Wilson J; Zhang PL
    Pathol Res Pract; 2016 Nov; 212(11):972-979. PubMed ID: 27640314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis.
    Monich AG; Cunha MFMD; Barreto FC
    J Bras Nefrol; 2023; 45(4):503-505. PubMed ID: 37497829
    [No Abstract]   [Full Text] [Related]  

  • 38. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs.
    Vekeman F; Magestro M; Karner P; Duh MS; Nichols T; van Waalwijk van Doorn-Khosrovani SB; Zonnenberg BA
    J Med Econ; 2015; 18(12):1060-70. PubMed ID: 26201433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal tumors in tuberous sclerosis complex.
    Trnka P; Kennedy SE
    Pediatr Nephrol; 2021 Jun; 36(6):1427-1438. PubMed ID: 33006051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
    Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B
    Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.